Mysildecard (Sildenafil)

Sildenafil, the active ingredient in Mysildecard, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral dosage form for oral use. It treats erectile dysfunction and pulmonary arterial hypertension in adult patients. GNH USA supplies Mysildecard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mysildecard, a PDE5 inhibitor, acts on the nitric‑oxide‑cGMP pathway to improve vascular smooth‑muscle relaxation in specific conditions.

Erectile dysfunction: enhances ability to achieve and maintain an erection sufficient for sexual activity. Pulmonary arterial hypertension: lowers pulmonary vascular resistance and improves exercise capacity. Diabetes‑related sexual dysfunction: improves erectile response in men with diabetes.

Sildenafil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache - Facial flushing - Dyspepsia or indigestion - Nasal congestion - Visual disturbances (e.g., blurred vision, color tinge) - Myalgia or back pain

Serious or Rare Side Effects: - Priapism (prolonged erection lasting >4 hours) - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy) - Sudden hearing loss or tinnitus - Myocardial infarction or severe cardiac events - Stroke or transient ischemic attack - Severe hypotension, especially with nitrate use

Before prescribing Mysildecard, clinicians should evaluate patient‑specific risk factors and contraindications. - Cardiovascular assessment: ensure the patient can safely engage in sexual activity. - Nitrate use: avoid co‑administration due to risk of profound hypotension. - Retinitis pigmentosa: use with caution as visual side effects may be exacerbated. - Concomitant alpha‑blockers: monitor blood pressure closely. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Sildenafil can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin, isosorbide dinitrate): risk of severe hypotension. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase sildenafil exposure.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., tamsulosin): may cause additive blood‑pressure lowering. - Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): monitor for excessive hypotension.